GSK expands Asia-Pacific reach for Trelegy Ellipta with Singapore approval
GSK’s Trelegy Ellipta has been approved as a maintenance therapy for both asthma and COPD in Singapore.
GSK’s Trelegy Ellipta has been approved as a maintenance therapy for both asthma and COPD in Singapore.
What's Your Reaction?
